HC Wainwright Issues Pessimistic Forecast for SLDB Earnings

Key Points

• HC Wainwright has lowered its Q3 2025 earnings per share (EPS) estimates for Solid Biosciences, now forecasting a loss of ($0.45) per share, down from ($0.43).
• Several analysts have reduced their price targets for Solid Biosciences, with Barclays setting a new target at $10.00, down from $15.00.
• Solid Biosciences shares opened at $6.17 and have a market capitalization of $480.46 million, with an average rating of "Buy" according to market data.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Analysts at HC Wainwright lowered their Q3 2025 earnings estimates for Solid Biosciences in a research note issued on Wednesday, August 13th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($0.45) per share for the quarter, down from their previous forecast of ($0.43). HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences' Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.87) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.54) EPS, FY2026 earnings at ($2.01) EPS, FY2027 earnings at ($1.75) EPS and FY2028 earnings at ($0.78) EPS.

Several other brokerages have also issued reports on SLDB. Cantor Fitzgerald set a $16.00 price target on Solid Biosciences and gave the stock an "overweight" rating in a research note on Monday, July 21st. Wedbush dropped their target price on Solid Biosciences from $17.00 to $14.00 and set an "outperform" rating for the company in a research report on Wednesday, August 13th. Citigroup started coverage on Solid Biosciences in a research note on Thursday, June 26th. They issued a "buy" rating and a $14.00 target price for the company. Chardan Capital reissued a "buy" rating and set a $15.00 price target on shares of Solid Biosciences in a research note on Thursday, August 14th. Finally, Piper Sandler lowered their price objective on shares of Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating for the company in a report on Friday, May 16th. Two research analysts have rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company. According to data from MarketBeat, Solid Biosciences has a consensus rating of "Buy" and an average target price of $15.00.

Solid Biosciences Stock Down 3.5%

NASDAQ:SLDB traded down $0.2050 during midday trading on Friday, hitting $5.5950. The company had a trading volume of 396,582 shares, compared to its average volume of 1,919,238. The company has a market capitalization of $435.68 million, a PE ratio of -2.00 and a beta of 2.44. Solid Biosciences has a 52-week low of $2.41 and a 52-week high of $10.37. The stock's fifty day moving average price is $5.67 and its 200-day moving average price is $4.48.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09.

Hedge Funds Weigh In On Solid Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in SLDB. Adage Capital Partners GP L.L.C. increased its position in Solid Biosciences by 285.0% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 6,729,484 shares of the company's stock valued at $24,899,000 after purchasing an additional 4,981,400 shares during the period. Bain Capital Life Sciences Investors LLC lifted its position in shares of Solid Biosciences by 96.1% in the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company's stock worth $29,273,000 after purchasing an additional 3,877,087 shares during the period. Siren L.L.C. boosted its stake in shares of Solid Biosciences by 97.8% during the 1st quarter. Siren L.L.C. now owns 7,415,905 shares of the company's stock valued at $27,439,000 after purchasing an additional 3,666,864 shares in the last quarter. MPM Bioimpact LLC purchased a new position in shares of Solid Biosciences during the first quarter valued at about $6,077,000. Finally, Nantahala Capital Management LLC increased its position in shares of Solid Biosciences by 505.4% during the second quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company's stock valued at $8,295,000 after buying an additional 1,421,968 shares during the period. Institutional investors own 81.46% of the company's stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.